BRCA1/2 Flu Vaccine

Abramson Cancer Center at Penn Medicine

Status: Active, not recruiting

Conditions: BRCA2 Mutation; BRCA1 Mutation

Treatments: Biological: Seasonal influenza vaccine

Study type: Observational

Funder types: Other

Identifiers

NCT04499534

834194

UPCC 11119

Details and patient eligibility

About

To evaluate immune function in BRCA1/2 mutation carriers without cancer, specifically to determine whether immune function in healthy individuals with germline loss of function BRCA1/2 mutations, impacts overall immune health and fitness.

Enrollment: 50 estimated patients

Sex: All

Ages: 25+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Males and females
• Over age 25
• BRCA1 or BRCA2 pathogenic or likely pathogenic mutation
• No personal cancer history apart from non melanoma skin cancer, localized thyroid cancer, in situ cancers of any type
• Participants must sign the informed consent form

Exclusion criteria

• Are allergic to influenza vaccination
• Have received influenza vaccination within the past 6 months
• Require prednisone, methotrexate, or other immunosuppressing medications
• Have HIV infection
• Have a history of solid organ tumor or bone marrow transplant
• Require combination immunotherapy;
• Are on other studies requiring blood draws that might exceed 450 mL total during the period of the influenza vaccine study